Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT07455851

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • Illawarra Cancer care centre, Wollongong Hospital Wollongong, New South Wales, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Beijing GoBroad Hospital Beijing, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, China
  • Shanghai Liquan Hospital Shanghai, China
View Trial Details
Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations
  • Rigshospitalet ( Site 0802) Copenhagen, Capital Region, Denmark
  • Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804) Aarhus Nord, Central Jutland, Denmark
  • Odense Universitetshospital ( Site 0801) Odense, Region Syddanmark, Denmark
  • Rambam Health Care Campus ( Site 0903) Haifa, Israel
View all 21 locations
View Trial Details
Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope - Lennar Foundation Cancer Center Irvine, California, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Novant Health Cancer Institute Charlotte, North Carolina, United States
View all 75 locations
View Trial Details
Recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662

Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, +20 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
View all 114 locations
View Trial Details
Recruiting

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Cytokine Release Syndrome, +19 more
Locations
  • Berenson Cancer Center Los Angeles, California, United States
  • Mary Bird Perkins Cancer Center Baton Rouge, Louisiana, United States
  • Northwest Medical Specialties, PLLC Tacoma, Washington, United States
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders Bethesda, Maryland, United States
View Trial Details
Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Infirmary Cancer Care ( Site 0157) Mobile, Alabama, United States
  • Ironwood Cancer & Research Centers ( Site 0204) Chandler, Arizona, United States
  • Palo Verde Cancer Specialists ( Site 0105) Glendale, Arizona, United States
  • City of Hope - Phoenix ( Site 0202) Goodyear, Arizona, United States
View all 144 locations
View Trial Details
Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Colorado Blood Cancer Institute ( Site 7000) Denver, Colorado, United States
  • SCRI Oncology Partners ( Site 0100) Nashville, Tennessee, United States
  • Instituto Alexander Fleming ( Site 1404) Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Sanatorio Nuestra Senora del Rosario ( Site 1403) Rosario, Santa Fe Province, Argentina
View all 39 locations
View Trial Details

Related conditions